Abstract
Shasha Wang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Comparison of early characteristics of multisystemic inflammatory syndrome and Kawasaki disease in children and the course of Kawasaki disease in the pandemic
10.1186/s12887-024-04966-x · 2024
Alterations in the gut mycobiome with coronary artery disease severity
10.1016/j.ebiom.2024.105137 · 2024
The occurrence of coronary artery lesions in Kawasaki disease based on C-reactive protein levels: a retrospective cohort study
10.1186/s12969-021-00566-6 · 2021
Correlation analysis of gut microbiota derivatives with coronary artery disease severity and prognosis
10.31083/rcm26566 · 2025
CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease
10.1086/323155 · 2021
Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review
10.3389/fimmu.2023.1237670 · 2023
Predicting factors for refractory Kawasaki disease
10.4070/kcj.2010.40.5.239 · 2020
The gut microbiota-host partnership as a potential driver of Kawasaki syndrome
10.3389/fped.2019.00124 · 2019
Investigating the causal role of the gut microbiome in Kawasaki disease: mediating effects of immune cells
10.1007/s10067-025-07687-3 · 2025
Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
10.1016/j.critrevonc.2019.09.003 · 2019
Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease
10.1111/all.12558 · 2015
Metagenomic analysis demonstrates distinct changes in the gut microbiome of Kawasaki diseases children
10.3389/fimmu.2024.1416185 · 2024
The role of intestinal microbiota in cardiovascular disease
10.1111/jcmm.14195 · 2019
Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association
10.1161/cir.0000000000001295 · 2024
Our evolving understanding of Kawasaki disease pathogenesis: role of the gut microbiota
10.3389/fimmu.2020.01616 · 2020
Bacterial induction of B cell senescence promotes age-related changes in the gut microbiota
10.1038/s41556-023-01145-5 · 2023
Diagnosis, progress, and treatment update of Kawasaki disease
10.3390/ijms241813948 · 2023
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
10.1038/s41575-019-0258-z · 2020
Unusual presentation of Kawasaki disease with gastrointestinal and renal manifestations
10.2147/tcrm.s226624 · 2019
Expression of oxidative stress and inflammatory indicators for coronary artery disease in Kawasaki disease
10.4084/mjhid.2024.052 · 2024
Interleukin-35 enhances regulatory T cell function by potentially suppressing their transdifferentiation into a T helper 17-like phenotype in Kawasaki disease
10.1080/08820139.2023.2201283 · 2023
Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition
10.1186/s12969-018-0303-4 · 2019
Kawasaki disease may increase the risk of subsequent cerebrovascular disease
10.1161/strokeaha.120.032953 · 2022
Case series on the efficacy and safety of tocilizumab in IVIG-resistant Kawasaki disease: A retrospective analysis of five patients
10.2147/jir.s479879 · 2024
The intriguing link between the intestinal microbiota and cardiovascular disease
10.1055/s-0036-1597903 · 2017
Assessment of vascular and endothelial function in Kawasaki disease
10.1016/j.bj.2022.03.010 · 2023
Assessment of selected intestinal permeability markers in children with food allergy depending on the type and severity of clinical symptoms
10.3390/nu14204385 · 2022
Kawasaki disease and multisystem inflammatory syndrome in children: common inflammatory pathways of two distinct diseases
10.1016/j.rdc.2023.03.002 · 2023
Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury
10.1186/s40001-020-00406-5 · 2020
The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation
10.3389/fcimb.2022.903570 · 2022
Kawasaki disease: an update
10.1007/s11926-020-00941-4 · 2020
Implications of changing Z-score models for coronary artery dimensions in Kawasaki disease
10.1007/s00246-020-02501-0 · 2021
Autoimmune aspects of Kawasaki disease
10.18176/jiaci.0300 · 2019
Kawasaki disease: pathology, risks, and management
10.2147/vhrm.s291762 · 2022
Kawasaki disease
10.1542/pir.2023-006051 · 2024
Effects of changes on gut microbiota in children with acute Kawasaki disease
10.7717/peerj.9698 · 2020
Prediction of coronary artery lesions based on C-reactive protein levels in children with Kawasaki disease: a retrospective cohort study
10.1016/j.jped.2023.02.005 · 2023
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis
10.1126/science.1241165 · 2013
Interleukin-35 regulates peripheral T cell activity in patients with Kawasaki disease
10.1016/j.intimp.2021.107642 · 2021
Unraveling the gut: the pivotal role of intestinal mechanisms in Kawasaki disease pathogenesis
10.3389/fimmu.2024.1496293 · 2024
Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study
10.1186/s12969-021-00589-z · doi-reference
Alteration of the oral and gut microbiota in patients with Kawasaki disease
10.7717/peerj.15662 · doi-reference
Potential mechanisms and hypotheses for pathogenic microorganisms triggering Kawasaki disease
10.1007/s12016-025-09120-8 · doi-reference
scRNA+TCR-seq reveals the pivotal role of dual receptor T lymphocytes in the pathogenesis of Kawasaki disease and during IVIG treatment
10.3389/fimmu.2024.1457687 · doi-reference
Activin a suppresses peripheral CD8+ T lymphocyte activity in acute-phase Kawasaki disease
10.1186/s12865-021-00407-x · doi-reference
Tocilizumab for the treatment of intravenous immunoglobulin-resistant Kawasaki disease in children: Two case reports and literature review
10.2147/jir.s603769 · doi-reference
The reduced SCFA-producing gut microbes are involved in the inflammatory activation in Kawasaki disease
10.3389/fimmu.2023.1124118 · doi-reference
Kawasaki disease: insights into the roles of T cells
10.3389/fimmu.2025.1582638 · doi-reference
NLRP3 inflammasome: a novel insight into heart failure
10.1007/s12265-022-10286-1 · doi-reference
Advances in understanding Kawasaki disease-related immuno-inflammatory response and vascular endothelial dysfunction
10.1002/ped4.12341 · doi-reference
Dysbiosis of the gut microbiota as a susceptibility factor for Kawasaki disease
10.3389/fimmu.2023.1268453 · doi-reference
Epstein-Barr virus downregulates the α7 nicotinic acetylcholine receptor of CD8+ T lymphocytes might associate with coronary artery lesions in Kawasaki disease patients
10.1016/j.micinf.2023.105168 · doi-reference